Please provide your email address to receive an email when new articles are posted on . Long-term CRT-D use was tied to improved survival and time to adverse events vs. ICD therapy in patients with ...

MINNEAPOLIS - Medtronic, Inc. today announced CE (Conformité Européenne) Mark receipt and the European launch of its newest cardiac resynchronization therapy-pacemaker, Viva® CRT-P. The Viva CRT-P is ...

The European Society of Cardiology (ESC) Guidelines on cardiac pacing and cardiac resynchronization therapy (CRT) are published online today in European Heart Journal. The use of pacemakers continues ...

Early report on modular BioVAT patches in advanced stage C or D disease ...

Cardiac resynchronization therapy (CRT) has emerged as a cornerstone in the management of selected patients with chronic heart failure characterised by reduced left ventricular ejection fraction and ...

Today, the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Latin American Heart Rhythm Society (LAHRS) released a new clinical practice guideline on cardiac physiologic ...

Multiple societies covering cardiovascular medicine, electrophysiology, heart failure, and imaging have released updated appropriate use criteria (AUC) for various cardiac implantable electronic ...

Medtronic Inc announced the first United States implant of the InSync III Marquis implantable cardioverter-defibrillator (ICD) system and the start of a new clinical trial of the company's newest ...

Results from the Cardiac Resynchronization—Heart Failure (CARE-HF) study support the use of implantable cardiac-resynchronization devices in patients with heart failure due to left-ventricular ...

A health trust has apologised after it emerged that more than 160 patients with advanced heart conditions may have undergone an unnecessary procedure. The patients were fitted with a Cardiac ...

Ivabradine and propranolol performed about the same in postural orthostatic tachycardia syndrome, a small placebo-controlled ...

Cardiac resynchronization therapy has been shown to benefit patients with heart failure despite optimal medical therapy, but the effect on long-term outcomes is unknown. New research findings are ...